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Abstract
Previously, we reported that retigeric acid B (RB), a natural pentacyclic triterpenic acid isolated from lichen, inhibited cell
growth and induced apoptosis in androgen-independent prostate cancer (PCa) cells. However, the mechanism of action of
RB remains unclear. In this study, we found that using PC3 and DU145 cells as models, RB inhibited phosphorylation levels
of IkBa and p65 subunit of NF-kB in a time- and dosage-dependent manner. Detailed study revealed that RB blocked the
nuclear translocation of p65 and its DNA binding activity, which correlated with suppression of NF-kB-regulated proteins
including Bcl-2, Bcl-xL, cyclin D1 and survivin. NF-kB reporter assay suggested that RB was able to inhibit both constitutive
activated-NF-kB and LPS (lipopolysaccharide)-induced activation of NF-kB. Overexpression of RelA/p65 rescued RB-induced
cell death, while knockdown of RelA/p65 significantly promoted RB-mediated inhibitory effect on cell proliferation,
suggesting the crucial involvement of NF-kB pathway in this event. We further analyzed antitumor activity of RB in in vivo
study. In C57BL/6 mice carrying RM-1 homografts, RB inhibited tumor growth and triggered apoptosis mainly through
suppressing NF-kB activity in tumor tissues. Additionally, DNA microarray data revealed global changes in the gene
expression associated with cell proliferation, apoptosis, invasion and metastasis in response to RB treatment. Therefore, our
findings suggested that RB exerted its anti-tumor effect by targeting the NF-kB pathway in PCa cells, and this could be a
general mechanism for the anti-tumor effect of RB in other types of cancers as well.
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Introduction
Prostate cancer (PCa) is one of the most common malignant
tumors in males [1]. It proceeds from a localized, androgen-
dependent disease to the invasive and metastatic hormone-
refractory prostate cancer (HRPC), without any significant
prognostic benefit to conventional antitumor agents [2]. There-
fore, novel strategies targeting the molecular basis of PCa
progression are urgently required.
The pivotal nuclear factor kB (NF-kB), a well-documented
transcriptional factor, is critically important for control of cell
proliferation in mammals. In classical pathway, the typical NF-kB
dimers (p50/p65) are normally sequestered by binding to IkBa in
the cytoplasm. The IkBa subunit is phosphorylated at serine
residues 32 and 36 by the IKK, and then degradation through the
proteosomal pathway, the p50-p65-IkBa heterotrimer turning into
the p50–p65 heterodimer. The nuclear localization signals of NF-
kB protein are exposed and its p65 subunit is phosphorylated,
leading to nuclear translocation and transcriptional activation
potential, and finally inducing the expression of a large number of
target genes.[3,4] Compelling evidence has been demonstrated
that aberrant NF-kB regulation is associated with initiation and
progression of various types of human cancer, including PCa, by
regulating the expression of genes important for many steps of
tumorigenesis and progression [2]. For example, the typical NF-
kB genes Bcl-2 and survivin, correlated with cell survival; cyclin
D1, correlated with proliferation; cyclooxygenase-2 (COX22),
correlated with inflammation; matrix metalloproteinase29
(MMP29) and intercellular adhesion molecule (ICAM), correlated
with invasion; vascular endothelial growth factor (VEGF) and
plasminogen activator urokinase (PLAU), correlate with angio-
genesis [3,4,5]. It is observed that nuclear localization of NF-kB
p65 in primary tumors samples [6,7], suggesting that constitutive
NF-kB activation maybe an early event in PCa development and
have prognostic importance for primary tumors. Therefore,
intercepting NF-kB signaling might be an attractive antitumor
approach [4,5,8,9]. Suppression of NF-kB activity has been shown
to repress growth of a variety of cancer cells both in vitro and in vivo.
Furthermore, the anti-apoptotic activity of NF-kB plays a role in
the resistance of tumor cells to chemotherapeutic reagents and
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e38000radiation therapy [8]. In chemoresistant androgen-independent
PCa cells, NF-kB is constitutively activated due to the constitutive
IkB kinase (IKK) activity [4,5].
Our previous study have shown that retigeric acid B (RB), a
natural pentacyclic triterpenic acid, possesses ability to inhibit cell
growth and induce apoptosis in multiple cell lines, including of
PCa cells [10]. Down-regulation of the expression of Bcl-2, which
is one of the NF-kB-dependent genes, and activation of caspase
signaling are observed in RB-treated PC3 cells [10,11]. Addition-
ally, similar to the structure of RB, other plant-derived triterpe-
noids including of acetyl-11-keto-b-boswellic acid (AKBA), ursolic
acid and betulinic acid, have been reported to interfere with the
NF-kB pathway [12,13,14]. These finding prompted us to test the
hypothesis that RB may exert its anticancer effects in PCa through
modulation of NF-kB signaling. In the present study, we
demonstrated that RB down-regulated p65 phosphorylation and
nuclear translocation, and blocked the constitutive activation of
NF-kB signaling in androgen-independent PC3 and DU145 cells
and in C56BL/6 homografts mice.
Results
RB exhibits inhibitory effect on p65 phosphorylation in
carcinoma cells
We initiated the study to test whether RB triggered apoptosis
through inhibiting the expression and activation of NF-kB in PC3
and DU145 cells in which NF-kB signaling is constitutively
activated and contributed to their resistance to apoptosis due to
expression of NF-kB-modulated antiapoptotic proteins. As shown
in Figure 1A and 1B, RB showed slight inhibitory effect on the
expression of total p65 subunit of NF-kB in PC3 and DU145 cells
(1.1,1.3-fold decrease for the highest dose), whereas significantly
down-regulated phosphorylation of p65–Ser536 was both dose-
and time-dependent (4,6-fold decrease for the highest dose or
48 h). Similar to the observations of the protein levels of total p65,
quantitative PCR data revealed that the mRNA level of p65 was
inhibited by RB treatment in a moderate manner (Figure 1C, 1D).
Treatment of PC3 and DU145 cells with 10 mM of RB for 24h
resulted in a ,35% decrease of the mRNA level of p65 compared
to the vehicle control (Figure 1C, 1D).
To extend our observation of decreased phosphor-p65 in PCa
cells, we detected the levels of total p65 and phosphor-p65 in other
cancer cell lines. The results revealed that RB was able to reduce
p65 phosphorylation in a panel of carcinoma cell lines including
Human liver hepatocellular cells HepG2 cells, human myeloid
leukemia cell line K562 cells and adriamycin-resistant K562/AO2
cells in indicated dose, whereas slight effect on human ovarian
cancer SKOV3 and human lung adenocarcinoma A549 cells
(Figure S1). Together, the data suggested that RB played a
profound effect on suppression of p65 phosphorylation, especially
in PCa cells.
RB suppresses the nuclear translocation and activation of
NF-kB in PCa cells
We then tested whether RB-mediated suppression of phosphor-
p65 led to a decrease in nuclear localization of p65 in PC3 cells,
which is necessary for NF-kB to activate target gene transcription.
As shown in Figure 2A, RB dramatically reduced the abundance
of phosphor-p65 in the nucleus in a dose-dependent manner, and
the decreased levels of phosphor-p65, to some extent were
observed in cytoplasm as well. The immunofluorescence results
in Figure 2B further confirmed that, similar to the western blot
assay, the significantly decreased nuclear accumulation of p65 was
clearly observed, whereas p65 was diffusely presented throughout
the cytosol and the nucleus in untreated cells.
Electrophoretic mobility shift assay (EMSA) was next done to
test whether RB affected NF-kB DNA binding ability in PC3 cells.
A strong band shift was detected when nuclear extract from
untreated control cells (lane 4 in Figure 2C), whereas binding
complexes were noticeably reduced in RB-treated cells in dose-
dependent manner (Figure 2C, lanes 5 and 6). The specificity of
NF-kB binding was confirmed in competition experiments with a
100-fold molar excess of unlabeled NF-kB (Figure 2C, lane 2).
AKBA, served as a positive control, decreased the binding activity
of NF-kB as well (Figure 2C, lane 3).
In an attempt to determine whether RB correspondingly
inhibited NF-kB transcriptional activity, we performed transient
transfection assays using a reporter plasmid containing 4 tandem
kB binding sites upstream of the luciferase gene. As shown in
Figure 2D, RB caused a significant decrease (p,0.05) in NF-kB
reporter activity in PC3 cells as compared to the untreated cells.
Ectopic expression of p65 (RELA) resulted in a significant up-
regulation of NF-kB luciferase activity, which can also be greatly
decreased (p,0.001) after treatment with RB (Figure 2D). Similar
results were obtained in DU145 cells under the same experimental
conditions (Figure 2E).
To investigate that RB was able to suppress inducible NF-kB
activity, we performed NF-kB reporter assay in LNCaP cells.
Unlike PC3 or DU145 cells, LNCaP cells are known to have low
NF-kB activity. As shown in Figure 2F, NF-kB-dependent reporter
activity was slightly increased after treatment with NF-kB-
inducing factor LPS alone. However, luciferase production was
profoundly augmented in cells by overexpression of p65 (RELA).
The activity of NF-kB was further dramatically decreased in cells
exposed to RB. These data demonstrated that RB suppressed both
the inducible (by LPS) and constitutive NF-kB activity in PCa
cells, possibly through RB-mediated down-regulation of phos-
phorylation, nuclear translocation and DNA binding ability of NF-
kB.
RB inhibits IkBa phosphorylation and its degradation
To investigate whether RB-mediated inactivation of NF-kB was
ascribed to the inhibition of IkBa degradation, we examined the
change of IkBa in response to RB by western blot analysis. As
shown in Figure 3A, treatment with increased concentrations of
RB resulted in overexpression of total IkBa in both PC3 and
DU145 cells. Correspondingly, reduced IkBa phosphorylation was
noted after treatment with 10–20 mM of RB in these two cell lines.
Time kinetic studies revealed that RB up-regulated the expression
of total IkBa, and caused a decrease in the phosphorylation of
IkBa from ,12 h in PC3 cells (Figure 3B). Similar effect was
observed in DU145 cells after longer (24 h) treatment with RB
than that in PC3 cells (Figure 3B). Proteasome activity assay
revealed that RB did not exert inhibitory effect on recombinant
20S proteasome enzyme (Figure 3C), which is required for
phosphorylatoin-dependent IkBa degradation. Thereby the data
suggested that down-regulated of IkBa degradation and p65
phosphorylation may be due to the effective suppression of IKK
activation by RB, which eventually lead to the inhibition of NF-kB
activity.
RB represses the expression of NF-kB-regulated genes,
induces apoptosis, and decreases cell migration through
the inhibition of NF-kB pathway
Since NF-kB regulates a variety of genes that are involved in the
cell growth, apoptosis, angiogenesis and metastasis of tumor cells,
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transcriptionally lead to the modulation of these gene products.
Treatment of RB significantly decreased the expression of Bcl-xL,
Bcl-2, survivin, and cyclin D1 at both mRNA (Figure 4A) and
protein levels (Figure 4B) in either PC3 or DU145 cells in a
dosage-dependent manner. Survivin, a known antiapoptotic
protein, was also markedly reduced in RB-treated cells as shown
in Figure 4B.
Inhibition of NF-kB by RB led us to further analyze the impact
of RB on cell invasion. As shown in Figure 4C, the invasiveness
through matrigel was concentration-dependently decreased in RB-
treated PC3 and DU145 cells when compared to vehicle treated
cells. As summarized in Figure 4D, RB treatment resulted in
significant block of cell migration in a dosage-dependent manner.
These results indicated that reduced activation of NF-kBb yR B
subsequently suppressed NF-kB-dependent antiapoptotic and
invasive proteins, leading to the decrease of tumor cell invasion.
To evaluate the changes of global gene expression in PC3 cells
after treatment with RB, Affymetrix GeneChip Human Genome
U133 Plus 2.0 array, which contained approximately 39,000
characterized human genes, were used to perform the experiment.
A total of 855 genes were upregulated greater than two-fold
change, and 763 genes downregulated in RB-treated PC3 cells
compared to control cells. The results in supplementary data
Figure 1. The effect of RB on p65 expression and phosphorylation in PCa cells. (A) and (B) RB slightly inhibited expression of p65 in PC3
and DU145 cells, while significantly for the Ser-536 phosphorylation of p65 (p–p65), in both dosage-dependent and time-dependent manner. Lysates
from whole cells treated with RB of different concentrations for 24 h (A) or with 10 mM RB for indicated times were used for western blot (B). GAPDH
served as the loading control. Protein amount was normalized to the amount of GAPDH, and was quantified by densitometry of X-ray films. Results of
one of at least three independent experiments are shown. (C) and (D) RB moderately down-regulated p65 mRNA level in PC3 and DU145 cells as
detected by QRT-PCR assay. The procedure was performed as described in Materials and Methods. Results shown are representatives of three
independent experiments, p,0.05 (*), versus RB-untreated control group respectively.
doi:10.1371/journal.pone.0038000.g001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e38000Figure 2. The effects of RB on function of NF-kB in vitro. (A) RB dosage-dependently inhibited the nuclear localization of p65 Lysates from
cytoplasm and nucleus respectively after treating of PC3 cells with RB for 24 h were used for western blot. GAPDH and H1 respectively served as the
loading control. (B) Immunofluorescence analysis of the inhibitory nuclear localization of p65 by RB-treatment for 12 h in PC3 cells. For confocal
microscopy, a-tubulin and p-p65 were immunostained, with nuclei stained with DAPI. (Scale bar, 10 mm). (C) Pretreatment of PC3 cells with RB
inhibited binding of nuclear extracts to the NF-kB binding site, as detected by electrophoretic mobility shift assay. Lysates from nuclei after treating
of PC3 cells with RB for 24 h were used for EMSA. (D), (E) and (F) RB decreased NF-kB activation in PC3 and DU145 cells, and inhibited LPS-induced
NF-kB activation in LNCaP cells. The inhibition was more significant when pNF-kB-Luciferase and RELA expression vector co-transfected. Transiently
transfected cells were preincubated with RB for 24 h. The luciferase assay was done as described in Materials and Methods. In (D)–(F), results are the
mean 6 S.E. of three independent experiments, each performed in triplicate. p,0.05 (*), p,0.01 (**), p,0.001 (***) versus RB-untreated control
group respectively.
doi:10.1371/journal.pone.0038000.g002
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kB-associated genes, in addition to other cell proliferation- and
survival-associated genes, and apoptotic regulatory genes present-
ed obviously alteration (.=1.5-fold). These results are mostly in
line with our data described. Many typical genes, such as Bcl-xL,
cyclin D1, p27, p21, etc. were down-regulated in RB treated
sample (Figure S2), therefore, further confirmed RB inhibits NF-
kB signaling and its downstream target gene expression.
To determine whether p65 (RELA) plays an important role in
RB-inducted apoptosis in PCa cells, we tested the effect of RB on
cell viability in cells that are either over-expressed with or ablated
for p65 by siRNA. It was observed that p65 expression plasmid
indeed enhanced the expression and phosphorylation levels of p65
over the basal levels (Figure 5A), and resulted in a partial rescue of
the consequences for RB-induced cell death in both PC3 and
DU145 cells (Figure 5B), indicating that p65 conferred cell
resistance to apoptosis induced by RB.
In the siRNA experiment, we chose the one of p65-targeting
siRNA that exerted the strong activity to deplete p65 expression
for evaluation of cell survival (data not shown). As shown in
Figure 5C, the expression and phosphorylation of p65 was
noticeably abolished in cells transfected with p65-targeting siRNA,
as compared to the scramble siRNA. The knockdown of p65
significantly suppressed cell growth (Figure 5D), and RB treatment
resulted in much lower level of phosphor-p65 and PARP (116
kDa) in p65-depleted cells and (Figure 5C), leading to the more
pronounced inhibition on cell viability. Therefore, these results
indicated that NF-kB p65 was essential for RB-induced cell death.
Figure 3. RB inhibits phosphorylation and degradation of IkBa. (A) Western blot analysis of expression of total IkBa and phosphor-IkBa (p–
IkBa, Ser32/36)p-IkBa. PC3 and DU145 cells were treated with RB of different doses as indicated. (B) Western blot analysis of expression of total IkBa
and p-IkBa. PC3 and DU145 cells were treated with RB of different times as indicated. In (A) and (B), equal protein loading was evaluated by GAPDH.
Protein amount was normalized to the amount of GAPDH, and was quantified by densitometry of X-ray films. Results of one of at least three
independent experiments are shown. (C) The effect of RB on the purified 20S proteasome in vitro. MG132 served as positive control. Results are the
mean 6 SD of three independent experiments, p,0.05 (*), p,0.01 (**), versus untreated control group respectively.
doi:10.1371/journal.pone.0038000.g003
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p65 phosphorylation in the tumor tissue of mice
Having demonstrated the efficacy of RB for blocking NF-kB
signaling in PCa cells in culture, we next investigated its potential
antitumor effect in mice. In particular, we performed studies to
investigate the expression and activation of p65 in tumor tissues of
mice. Firstly we examined the cytotoxic activity of RB and AKBA.
RB and AKBA remarkably reduced RM-1 cell growth (data not
shown). More importantly, RB and AKBA significantly suppressed
phosphorylation of p65 in RM-1 cells at desired concentrations
(Figure 6A). Thus, this cell line is equivalent to its human
counterparts and was used for establishment of PCa homografts in
male C57BL/6 mice. After planting RM-1 cells subcutaneously
into C57BL/6 mice, we treated mice by daily intraperitoneal
injections with 25 mg/kg of RB started 7 days after cell
inoculation and continued for another 18 days. Group of
treatment with 25 mg/kg of AKBA served as the positive control.
Compared to receiving vehicle control group, RB- or AKBA-
treatment significantly reduced the average tumor volume after
6th, 12th and 18
th days of treatment, RB group displayed a more
powerful potential (Figure 6B and 6C). The results in Table 1
revealed that, tumor weights were also decreased significantly in
Figure 4. The effects of RB on function of NF-kB-dependent gene expresion and cell invasion in vitro. (A) RB dosage-dependently
inhibited the mRNA expression of Bcl-xL, Bcl-2, survivin, and cyclin D1 as analyzed by QRT-PCR. GAPDH was used for normalization. Results are the
mean 6 SD of three independent experiments, each performed in triplicate. p,0.05 (*), p,0.01 (**), p,0.001 (***) versus RB-untreated control group
respectively. (B) RB dosage-dependently inhibited expression of Bcl-xL, Bcl-2, survivin, and cyclin D. The results of western blot analysis of whole cell
lysates from PC3 cells treated with different doses of RB were shown; GAPDH was included as a loading control. (C) RB inhibited invasion of PCa cells
in a concentration-dependently manner as detected by transwell assay, (scale bar, 100 mm). The procedure was described in Materials and Methods.
(D) The number of cells that invade through matrigel.
doi:10.1371/journal.pone.0038000.g004
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group (p,0.001). The inhibition rates of tumor weight of RB and
AKBA groups were 49.60% and 30.01%, respectively. TUNEL
staining demonstrated that, in contrast to the tumor tissues
receiving vehicle, increasing numbers of TUNEL positive stained
apoptotic cells were seen in the tumor tissues from RB or AKBA
treated mice (Figure 6D, right panel). These apoptotic cells were
recognized in the whole section of the tumor issues treated with
chemicals. Histological H&E staining (Figure 6D) showed the
morphologic changes in the tumor tissues. In contrast to control
group, RB or AKBA treatment caused an increase in the fraction
of apoptotic cells with shrinkage cytoskeleton and condensed
nucleus, suggesting that tumor tissues responded to RB or AKBA
with increased rates of apoptosis.
To gain insights in the mechanistic basis for RB’s antitumor
activity, we investigated the expression status of various proteins
associated with apoptosis and particularly activation of NF-kBi n
the target tissues. As shown in Figure 6E, RB produced a profound
inhibition of PARP, Bcl-2, and Bcl-xL expressions in tumor tissues
from treated mouse groups, whereas caused a striking increase in
the expression of Bax, consistent with the results in culture cells.
Notably, delivered RB in mice suppressed activation of NF-kB, as
indicated by the reduction of phosphor-p65 expression in tumor
tissues when compared to the vehicle control groups. Immunoflu-
orescence analysis of the tumor sections for phospho-p65 revealed
that, similar to the effect of AKBA, RB notably inhibited
phosphorylation and localization of p65 in situ (Figure 6F).
Together, the data demonstrated that RB exerted antitumor
activity against PCa homografts in C57BL/6 mice, by inactivation
of NF-kB signaling and induction of apoptosis.
Discussion
RB, a member of natural pentacyclic trieroenic acids, has been
recently gained our attention for its potential antitumor activity in
PCa [10].
In this study, we found that RB was a potent inhibitor of NF-kB
in PCa cells. Firstly, RB inhibited phosphorylation of p65 on Ser-
536 in vitro and in vivo. Secondly, RB inhibited IkBa phosphor-
ylation and degradation, eventually leading to the inhibition of
Figure 5. RELA is involved in RB-induced apoptotic cell death. (A) and (B) RELA overexpression by transfection of a RELA expression vector
partially abolished cytotoxicity in PC3 and DU145 cells. Cells were transfected with siRNA of RELA (RELAi) or with a negative control siRNA (NCi), using
a 50 nmol/L final siRNA concentration. After 48 h transfection for RELA overexpression, the effect of RB on p65, p–p65, and PARP expression in RELA
transfected cells was determined by western blot; cell viability was also determined after additional exposure for 24 h to RB. (C) and (D) Silencing of
RELA expression by siRNA increased cytotoxicity induced by RB. Similar procedure was performed for the studies on RELA. The details are described in
Material and Methods. In (A) and (C), the protein levels of p65 and p–p65 were normalized with GAPDH. Results shown are representatives of three
independent experiments. In (B) and (D), p,0.05 (*), p,0.01 (**), p,0.001(***) versus RB-untreated control group, respectively.
doi:10.1371/journal.pone.0038000.g005
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inhibitory effect on NF-kB activity by RB was also reflected by the
reduced expressions of NF-kB-dependent genes such as bcl-2, bcl-
xL, cyclin d1, and survivin, and the final consequence of the
inhibition of NF-kB in PCa cells. Overexpression and knockdown
experiments supported the observations that the reduction of p65
by RB was crucial in its apoptotic modulation. In addition to PCa
cells, suppression of NF-kB activation by RB was observed in
Figure 6. RB inhibits growth of RM-1 homografts in C57BL/6 mice and triggers apoptosis. (A) RB and AKBA concentration-dependently
inhibited the Ser-536 phosphorylation of p65 in RM-1 cells. GAPDH served as the loading control. (B) RB (25 mg/kg) reduced the tumor volumes in
RM-1-bearing C57BL/6 mice versus the control group, AKBA serving as positive control. 0.2610
6 RM-1 cells were s.c. injected into the dorsal region of
right side, and after 7 days, the animals were treated intraperitoneally with RB (25 mg/kg), AKBA (25 mg/kg) or medium alone (control) once daily for
18 days, as described in Materials and Methods, n=6 per group; mean 6 SD; p,0.05 (*), p,0.01 (**), p,0.001(***) versus medium control group,
respectively. (C) Representative tumors from the three groups are shown. (D) H&E and TUNEL-dependent staining of RM-1 tumor tissue sections.
(Scale bar, 100 mm). (E) Western blot analysis of p–p65, PARP, Bax, Bcl-2, and Bcl-xL expression in 2 tumor tissue samples treated with medium, 4
samples with RB and 2 samples with AKBA. (F) Immunofluorescence for p–p65 analysis of tumor tissues. (Scale bar, 100 mm).
doi:10.1371/journal.pone.0038000.g006
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(K562, AO2), and liver hepatocellular cells (HepG2), indicating
that inactivation of NF-kB by RB is a general mechanism for its
antitumor activity.
As known, the mechanism of NF-kB activation in cells on
stimulation is primarily dependent on the phosphorylation and
ubiquitination of the inhibitory proteins IkBs and subsequent
subjected for degradation by the 26S proteasomes. We found that
RB had no effect on the activity of 20S proteasome, suggesting
that inhibition of IkB degradation and inactivation of NF-kB p65
by RB was mainly due to a step upstream of IkBa phosphory-
lation. The classic regulation pattern is inhibition of IKK activity,
which in turn leading to the reduction of phosphor-IkBa. Whether
IKK is direct target of RB and inactivation of IKK by RB is
essential for its inhibitory effects on IkB/ NF-kB remains to be
elucidated in the future work. In addition to classical NF-kB, RB
didn’t alter the expression of p50 and p52 in PCa cells (data not
shown), suggesting that the nonclassical NF-kB pathway is not
essential in RB-mediated cell death.
As expected, in this study we found the pattern of activity
modulation of RB was similar to that of other natural pentacyclic
triterpenic acids. AKBA, ursolic acid and betulinic acid directly or
indirectly interact with IKK and inhibit NF-kB signaling
[12,13,14]. This biological characteristic is observed in a variety
of different cell lines, including human PCa (PC3 and DU145),
human leukemia (Jurkat cells), human embryonic kidney (293
cells), human myelogenous leukemia (KBM-5), human non-small
cell lung carcinoma (H1299), and human histiocytic lymphoma
(U937), colon cancer (HCT116 and Caco2) and pancreatic cancer
(PANC-28) [12,13,14,15,16,17]; these findings suggest that natural
pentacyclic triterpenic acids can be broad inhibitors of NF-kB
activation.
However, suppression of some gene products by pentacyclic
triterpenic acids seems to be selective Our data showed that VEGF
and COX22 expressions remained unchanged in PC3 cells
exposed to RB (data not shown). Other groups’ studies have
reported that AKBA suppresses VEGF expression in plasmacyto-
ma U266 cells [18], and inhibits COX22 mRNA expression
induced by TNF in KBM-5 cells [19]. In accordance with AKBA,
ursolic acid and betulinic acid also trigger reduction of VEGF and
COX22 level in other cell lines, including human leukemia cell
line Jurkat, human epithelial cell line HCT116, lung cancer cell
lines A549, H3255 and Calu-6, human PCa cell line PC3, human
colon cancer cell lines RKO and SW480. [13,14,20,21]. The
effects of plant-derived pentacyclic triterpenic acids on NF-kB
signaling pathway may be varied due to the different substituted
groups in pentacyclic triterpenes, and/or cell type-dependent.
Collectively, our findings suggest that RB promotes apoptosis
through suppression of NF-kB activation and NF-kB-dependent
antiapoptotic gene expression in PCa cells and animal models, and
NF-kB signaling pathway represents an important molecular
target for anticancer activity of RB.
Materials and Methods
Chemicals
Retigeric acid B (RB) was isolated from lichen L. kurokawae, and
its purity and structure determination was described previously
[22]. Acetyl-11-keto-b-boswellic acid (AKBA) was isolated and
purified by reverse phase high performance liquid chromatogra-
phy as described previously [22]. The compounds were dissolved
in dimethyl sulfoxide (DMSO) at 10 mM as stock solutions stored
at 220uC and diluted according to experimental requirements
when used. For the application of RB in the homograft models we
developed a solvent system consisting of physiological saline/
DMSO/ethanol/tween 80 (75:10:10:5, v/v).
Cell Culture and Homografts
Human PCa LNCaP (The American Type Culture Collection,
Rockville, MD), PC3, DU145 cells, and murine PCa RM-1 cells
(The Cell Bank of Chinese Academy of Sciences, Shanghai) were
cultured in RPMI 1640 medium (HyClone) supplemented with
10% FBS (HyClone). Human lung adenocarcinoma A549 cells
were cultured in Ham’s /F-12 (HyClone) supplemented with 10%
FBS (HyClone). Human liver hepatocellular cells HepG2, human
ovarian cancer cells SKOV3, human myeloid leukemia cell line
K562 and adriamycin-resistant K562/AO2, were cultured in
RPMI 1640 medium (HyClone) supplemented with 10% FBS
(HyClone).
RM-1 cells from C57BL mouse prostate tumors are androgen-
independent and can be transplanted into the syngeneic mice to
reconstitute the homotransplantation, which is suitable model to
simulate human PCa. [23,24] For homotransplantation male
C57BL/6 mice of aged 7 weeks (Vital River Laboratories, Beijing)
were inoculated subcutaneously in the backs with 0.2610
6 RM-1
cells in 0.2 ml of physiological saline [23]. After 1 week, treatment
commenced by single daily intraperitoneal injections of RB or
AKBA at 25 mg/kg or equivalent amounts of solvent for
additional 18 days [12]. The tumor size was measured by 6 days
with a caliper; the tumor volume was calculated according to the
formula 0.56L 6W
2 (L=length, W = width). At the end of the
experiment, all mice were euthanized by air-ether anesthesia and
their tumors resected. The tumors were prepared frozen tissue
slices (5 mm thick). Proteins extracted from each tumor tissue were
used for western blot. All animal experiments were approved by
the Ethics Committee of Shandong University School of Medicine
(Permit Number: 2010037) and conducted accordingly.
MTT Assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT, Sigma) colorimetric assay was used to quantitate
PC3, DU145 and RM-1 cells proliferation and cytotoxicity in the
presence of RB. Cells (1610
4 per well) were seeded into 96-well
plates. After 24 hours incubation, the cells were treated with
vehicle, or desired concentrations of RB for further 24 hours. After
removing the medium, incubate cells with 10 ml MTT for 4 hours.
The cell growth response to the chemicals was detected by
measuring the light absorbance at 570 nm on a plate reader (Bio-
rad, USA).
Western Blot Analysis
After treatment with RB at desired concentrations for 24 hours
or with 10 mM RB for desired times, whole cell lysates was
obtained according to the method described previously [25]. The
procedures for western blot were described previously [26]. Blots
were incubated with primary antibodies against p65, survivin
(Santa Cruz Biotechnology), phosphor-p65 (Ser536), phosphor-
Table 1. Effect of RB on tumor growth (n=6, mean 6 S.D.)
Group
Control RB (25 mg/kg) AKBA (25 mg/kg)
Tumor weight (g) 2.3860.21 1.1960.29*** 1.6660.26***
Inhibition rate (%) 49.60*** 30.01***
***P,0.001 compared with Control group.
doi:10.1371/journal.pone.0038000.t001
Retigeric Acid B Inhibits NF-kB Signaling
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e38000IkBa (Ser32/36), IkBa, Bcl-xL, Bcl-2, Bax, total and cleaved
PARP (Cell Signaling Technology), cyclin D1 (NeoMarkers).
Membranes were stripped and reprobed with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology)
as a protein loading control. H1 (Bioworld) served as the loading
control for nucleoprotein.
Quantitative RT-PCR Analysis
Quantitative real-time PCR (QRT-PCR) assay was carried out
to analyze the mRNA level of p65 in PC3 and DU145 cells treated
with 10 mM RB for desired times, and Bcl-xL, Bcl-2, survivin,
cyclin D1, PCNA, cyclin B1, p27, p21, H2AX, DDIT4, EGF,
ATM and GAPDH with RB-treatment for 24 hours. Total RNAs
of PC3 and DU145 cells were extracted by Trizol (TaKaRa).
cDNA was synthesized through reverse transcription using
ReverTra AceH qPCR RT Kit (TOYOBO). QRT-PCR was
performed using the Eppendorf QRT-PCR System. Primers for
p65, Bcl-xL, Bcl-2, survivin, cyclin D1, PCNA, cyclin B1, p27,
p21, H2AX, DDIT4, EGF, ATM and GAPDH were 59-
GGGAAGGAACGCTGTCAGAG-39 (forward) and 59-TACCT-
CAGGGTACTCCATCA-39 (reverse); 59-
GGTCGCATTGTGGCCTTCTT-39 (forward) and 59-
CTCTCGGCTGCTGCATTGTT-39 (reverse); 59-
TGTTGGCCGGATCACCAT-39 (forward) and 59-
TCCCCAATGATCAGGTCCTTT-39 (reverse); 59-AGGAC-
CACCGCATCTCTACAT-39 (forward) and 59-
AAGTCTGGCTCGTTCTCAGTG-39 (reverse); 59-CAAACA-
GATCATCCGCAAACA-39 (forward) and 59-
GCAGTCTGGGTCACACTTG-39 (reverse); 59-TGGTCAC-
CAGGGCTGCTT-39 (forward) and 59-AGCTTCCCGTTCT-
CAGCCTT-39 (reverse); 59-ACACTAAGGGCCGAAGA-
TAACG-39 (forward) and 59-
CGGCATATACGTGCAAATTCAC-39 (reverse); 59-
ATAAGGCGAAGATCAACATGGC-39 (forward) and 59-
TTTGTTACCAATGTCCCCAAGAG-39 (reverse); 59-
TAATTGGGGCTCCGGCTAACT-39 (forward) and 59-
TTGCAGGTCGCTTCCTTATTC-39 (reverse); 59-
CCTGTCACTGTCTTGTACCCT-39 (forward) and 59-
GCGTTTGGAGTGGTAGAAATCT-39 (reverse); 59-
TTGGTAACAGGCACATCTTCCT-39 (forward) and 59-
TTCCGCAAAACGACTCTTG-39 (reverse); 59-AGCGGCAG-
GACGCACTTGTC-39 (forward) and 59-
GGCCGATCTGGGGTGGGAGT-39 (reverse); 59-CAAACA-
CACTGGAAAGGACATGG-39 (forward) and 59-
ATCTTCTGCCTTGGGTTGTGC-39 (reverse); 59-
TGATGCTTTCTGGCTGGATTT-39 (forward) and 59-GCAG-
CACAAGACTGAGCTACC-39 (reverse), respectively. GAPDH
gene was co-amplified to serve as an internal control.
Electrophoretic Mobility Shift Assay (EMSA) and Nuclear
Translocation of Transcription Factor p65
The oligonucleotides used for an NF-kB binding site (Promega),
were 59-AGTTGAGGGGACTTTCCCAGGC-39, labeled with
digoxigenin at 39 end by the terminal transferase method. Nuclear
extracts (10 mg/sample) from PC3 cells with or without pretreat-
ment with RB or AKBA for 24 hours were subjected to EMSA
following the protocol provided by Roche [22]. For competition
studies, nuclear extracts (Nuclear and Cytoplasmic Protein
Extraction Kit, Beyotime) were incubated on ice for 30 minutes
with a 100-fold excess of unlabeled specific NF-kB oligonucleo-
tides. AKBA (30 uM) served as a positive control. In experiments
of nucleic localization of phosphor-p65 in PC3 cells, cytosol and
nuclear lysates extracted using Nuclear and Cytoplasmic Protein
Extraction Kit (Beyotime) were used for western blot. GAPDH
and H1, respectively served as the loading control.
Transient Transfection Assay
PC3, DU145 and LNCaP cells were seeded in 24-well plates
and grew under the conditions described above. The vectors pNF-
kB-Luciferase (NF-kB promoter, containing 4 tandem kB binding
sites upstream of the luciferase gene, 0.5 mg/well), or RELA
expression vector (0.15 mg/well) were transfected into cells using
Lipofectamine2000 (Invitrogen Life Technologies). The SV40
vector (0.8 mg/well) was used as a control. The phRL-TK vector
(0.05 mg/well, Renilla luciferase, Promega) was co-transfected to
normalize transfection efficiency. After 24 hours the cells were
exposed to RB for an additional 24 hours. Cell lysates were
prepared for luciferase assays (Dual-luciferase reporter assay
system, Promega). In experiments with lipopolysaccharide (LPS,
Sigma), 1 mg/ml of LPS was used to treat cells for 30 minutes after
the addition of the RB. In experiments to detect the cytotoxicity
and apoptosis parameters of RB after transfecting RELA, MTT
assay was performed after pretreating with RB for 24 hours. Cells
transfecting pcDNA3.1 (0.8 mg/well) served as the control.
Transwell Invasion Assays
Transwell invasion assays were performed with Growth Factor
Reduced Matrigel Invasion Chambers (BD Biosciences) according
to the manufacturer’s protocol. Briefly, PC3 or DU145 cells
pretreated with RB of different concentrations for 24 hours were
dissociated from the plates and 0.5610
6 cells were resuspended in
RPMI-1640 containing 1% bovine serum albumin into the upper
chamber in which matrigel matrix (BD Biosciences) was added.
RPMI-1640 containing 10% fetal bovine serum as a chemoat-
tractant was added to each bottom well. Cells were allowed to
invade for 48 hours at 37uC, then non-invaders were removed.
Invading cells were fixed and stained with the Gimsa stain
solution. Cells were counted, and the total number of cells per
chamber was used for calculating the number of invading cells.
Gene Silencing with Small Interfering RNA
Gene silencing was achieved by small interfering RNA (siRNA)
of RELA transfection. Sense sequences of three RELA siRNAs
(synthesized from Invitrogen) are 59 -UUCACUCGGCAGAU-
CUUGAGCUCGG-39,5 9-AAACUCAUCAUAGUUGAUG-
GUGCUC-39,5 9-UUUACGUUUCUCCUCAAUCCGGUGA-
39, respectively. Negative control siRNA oligonucleotides (synthe-
sized from Invitrogen) target the sequence 59-AATTCTCC-
GAACGTGTCACGT-39. After transfecting the three siRNAs
(50 nmol/L) into PC3 cells respectively, and incubating for
48 hours, we evaluated their effects on RELA silencing via
western blot analysis and obtained the one with most remarkable
gene silencing effect. Then we treated PC3 and DU145 cells with
RB, as described previously, 48 hours after transfected the cells
using the RELA siRNA and the negative control siRNA with
Lipofectamine2000 (Invitrogen) according to the manufacturer’s
instruction. Effects of RB on the conditioned cells were evaluated
by western blot analysis and cell survival assay.
Proteasome activity assay
Proteasome activities were measured via the direct addition of
RB to purified 20S proteasome in vitro. The substrates N-Succinyl-
Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (suc-LLVY-AMC,
ML-P802) and Benzyloxycarbonyl-L-leucyl-leucyl-glutamyl-
methylcoumarylamide (Bz-LLE-AMC, ZW9345) were incubated
at 37uC for 40 minutes with pure 20S proteasome (human
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ed 5 mM, 10 mMR Bo r1 0mM MG132 (#474790, Calbiochem)
in assay buffer. Fluorescene was determined by Mithras LB-940
(Berthold Technologies, Germany), with an excitation of 355 nm
and emission of 460 nm.
Immunofluorescence, H&E Staining and TUNEL Assay
The frozen sections obtained from mouse tumor tissues were
fixed in 4% paraformaldehyde, and processed for H&E staining
[27] or immunofluorescence for phosphor-p65 [28], nuclei
marked with DAPI (Sigma-Aldrich) staining. For the in situ
detection of apoptotic cells in tumor tissue sections, the terminal
deoxynucleotidyl transferase-mediated dUTP nickend labeling
(TUNEL) method was used (DNA Fragmentation Detection Kit,
Calbiochem). The sections were counterstained with Methyl
green. The images were digitally recorded at a magnification of
1006or 2006with an inverted microscope (Nikon).
For the immunofluorescence analysis of nucleic localization of
phosphor-p65 in PC3 cells, the confocal laser-scanning microscopy
(Carl Zeiss, LSM780) was used. The cells were treated with 10 mM
RB for 12 h. a-tubulin (Cell Signaling Technology) was immuno-
stained as a marker for the cytosol, whereas nuclei were stained
with DAPI; antibody against phosphor-p65 (Ser536, Cell Signal-
ing Technology) was used for the experiment.
Microarray Analysis
For this experiment, we used Affymetrix GeneChipH 39
expression arrays [29]. Total RNA was isolated after treating
PC3 cells with 10 mM RB or DMSO (control) for 24 hours. The
procedure followed the protocols developed by Affymetrix,
GeneChip 39 IVT Express Kit. Multi-array analysis (RMA) [29]
was performed using Affymetrix Expression Console software, and
Partek GS 6.5 software provided the results of data contrast
analysis.
Statistical Analysis
The data are presented as the mean 6 S.D. of at least three
independent experiments. The statistical significance of mean
difference between the control and treated groups was determined
by a paired t-test. P,0.05 was considered statistically significant.
Supporting Information
Figure S1 RB blocks NF-kB activation in a variety of
cancer cell types, to a different degree. We tested levels of
total p65 and phosphor-p65 in Human lung adenocarcinoma cells
A549, human liver hepatocellular cells HepG2, human ovarian
cancer cells SKOV3, human myeloid leukemia cell line K562 and
adriamycin-resistant K562/AO2, with indicated dose of RB for
24 h. GAPDH served as the loading control.
(TIF)
Figure S2 The validation of DNA microarray data by
QRT-PCR assay. We detected the 9 mRNA expression
alteration involved in PCNA, cyclin B1, p27, p21, H2AX,
DDIT4, EGF, ATM and GAPDH in PC3 cells with RB-treatment
for 24 h versus medium-treatment respectively, across the two
different methods.
(TIF)
Table S1 NF-kB family and NF-kB-associated genes,
other cell proliferation- and survival-associated genes
expression alteration p (.=1.5-fold) in PC3 cells treated
with 10 mM RB for 24 h with the DNA microarray
analysis.
(DOC)
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